Bausch Health Companies Investor Conference Presentation Deck
Accelerating Strategic Alternatives to Unlock Shareholder
Value¹
6
Complete financial
segmentation of Bausch +
Lomb
Appoint leadership of
Bausch Pharma² and
Bausch + Lomb
Achieve all internal
objectives needed for the
spinoff
Launch IPO of Solta
Medical in Dec. 2021/Jan.
2022 timeframe³
Launch Bausch + Lomb
IPO-30 days after Solta
Medical IPO³
Bausch + Lomb spinoff
following the expiry of
customary lock-ups and
achievement of our target
net leverage ratios4
BAUSCH- Health
Actively pursuing all opportunities to expedite leverage
improvement and deliver shareholder value
Bausch+Lomb Net Leverage
Targeting less than 2.5x
at time of spin
Path to
Deleveraging
Bausch Pharma² Net Leverage
Targeting ~6.5x-6.7x
at time of spin
Used Cash Generated from Amoun Divestiture
Initial Public Offering (IPO) of Solta Medical
Remaining Value of Solta Medical to Delever
Bausch + Lomb Debt Raise
IPO of Bausch + Lomb
Grow EBITDA and Improve
Working Capital Efficiency
This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities.
1. See Slide 1 for further information on forward-looking statements.
2. The remainder of Bausch Health is referred to as "Bausch Pharma" and will assume a new name upon the separation of the Company's eye health business, Bausch + Lomb.
3. Subject to market conditions and regulatory, stock exchange and other approvals.
4. Subject to receipt of applicable shareholder and other necessary approvals.View entire presentation